Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo

Abstract

DNA vector-based Stat3-specific RNA interference (si-Stat3) blocks Stat3 signalling and inhibits prostate tumour growth. However, the antitumour activity depends on the efficient delivery of si-Stat3. The effects on the growth of mouse prostate cancer cells of si-Stat3 delivered by hydroxyapatite were determined in this study. RM-1 tumour blocks were transplanted into C57BL/6 mice. CaCl 2 -modified hydroxyapatite carrying si-Stat3 plasmids were injected into tumours, and tumour growth and histology were determined. The expression levels of Stat3, pTyr-Stat3, Bcl-2, Bax, Caspase3, VEGF and cyclin D1 were measured by western blot analysis. Amounts of apoptosis in cancer cells were analysed with immunohistochemistry and the terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick end-labelling (TUNEL) assay. The results showed that hydroxyapatite-delivered si-Stat3 significantly suppressed tumour growth up to 74% (P,0.01). Stat3 expression was dramatically downregulated in the tumours. The immunohistochemistry and TUNEL results showed that si-Stat3-induced apoptosis (up to 42%, P,0.01). The Stat3 downstream genes Bcl-2, VEGF and cyclin D1 were also strongly downregulated in the tumour tissues that also displayed significant increases in Bax expression and Caspase3 activity. These results suggest that hydroxyapatite can be used for the in vivo delivery of plasmid-based siRNAs into tumours.

Plasmid-based Survivin shRNA and GRIM-19 carried by attenuated Salmonella suppresses tumor cell growth

“…It has been shown to interact exclusively with the transcriptional activating domain of Stat3 and inhibited transcriptional activation. 27,28,38 Recent studies have also shown that GRIM-19 expression is reduced or eliminated in a number of primary tumors. 29,35 Survivin is a downstream target of Stat3.…”

STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers

“…Some other major problems of RNA delivery include rapid excretion by kidney, degradation in extracellular fluid and permeability to the cell membrane. Nevertheless, approaches using different delivery agents (liposome, nanoparticle and LNA oligonucleotide) have entered preclinical and phase I clinical trials (97,98).…”

Gene Delivery by Hydroxyapatite and Calcium Phosphate Nanoparticles: A Review of Novel and Recent Applications

“…There are some important weaknesses that limit the extensive application of several delivery systems such as the mutagenesis or oncogenesis potential, host immune responses, and high cost. As the immune response toward the non-viral siRNA delivery systems is very few, this yields an advantage in drug target validation and permits the therapeutic applications of siRNA [49].…”